Strides Shasun gets USFDA nod for Abacavir tablets
New Delhi : Strides Shasun said it has received an approval from the US health regulator for Abacavir tablets used in the treatment of HIV.
In a BSE filing, Strides Shasun said "it has received approval from the United States Food and Drug Administration (USFDA) for Abacavir Tablets USP, 300 mg".
The product will be manufactured at the company's USFDA approved facility at Bengaluru and marketed by Strides in the US market.
"The product will be launched immediately," it added.
According to IMS sales data, the US market for Abacavir is approximately USD 30 million.
Strides Shasun stock was trading 0.96 per cent higher at Rs 1,053 apiece on BSE in morning trade.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd